Form 4: Mirum Pharmaceuticals CSO, Pamela Vig, Executes Stock Option and Sells Shares Under 10b5-1 Plan

Pamela Vig, Chief Scientific Officer of Mirum Pharmaceuticals, exercised stock options and sold shares of common stock on June 24, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 24, 2024, Pamela Vig, the Chief Scientific Officer of Mirum Pharmaceuticals, exercised a stock option to purchase 30,559 shares of common stock at a price of $2.936 per share.
• Simultaneously, Vig sold 30,559 shares of common stock at $34 per share.
• Following these transactions, Vig directly owns 27,406 shares and indirectly owns 75,000 shares through The Vig-Ancock Family Trust.
• The reported transactions were executed under a Rule 10b5-1 trading plan adopted in March 2024.
• Vig also holds options to purchase 125,691 shares of common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the executive's outlook on the company.

Positives

• The execution of the stock options and subsequent sale of shares by the CSO indicates confidence in the company's future prospects, as the options were exercised before being sold.
• The use of a pre-arranged 10b5-1 trading plan demonstrates transparency and avoids concerns about insider trading.

Negatives

• The sale of shares by a key executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create short-term price volatility.
• Investor sentiment could be affected if there are concerns about the reasons behind the stock sales, despite the existence of the 10b5-1 plan.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are often part of compensation packages. The use of a 10b5-1 plan is a standard practice to ensure compliance with insider trading regulations.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units.
• Rule 10b5-1 plans are widely used by executives to manage their stock sales in a transparent and compliant manner.
• The exercise and sale of shares by Pamela Vig is consistent with typical executive compensation practices in similar biotech companies.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.
• Employees may be indirectly affected by any changes in investor sentiment resulting from the stock sales.

Key Dates